Summit's ezutromid reduces muscle damage in DMD

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) gained $1.57 (13%) to $13.78 in New York on Thursday after reporting interim 24-week data from the Phase II PhaseOut DMD

Read the full 263 word article

User Sign In